Literature DB >> 2111443

Oncogenic transformation by vrel requires an amino-terminal activation domain.

J Kamens1, P Richardson, G Mosialos, R Brent, T Gilmore.   

Abstract

The mechanism by which the products of the v-rel oncogene, the corresponding c-rel proto-oncogene, and the related dorsal gene of Drosophila melanogaster exert their effects is not clear. Here we show that the v-rel, chicken c-rel, and dorsal proteins activated gene expression when fused to LexA sequences and bound to DNA upstream of target genes in Saccharomyces cerevisiae. We have defined two distinct activation regions in the c-rel protein. Region I, located in the amino-terminal half of rel and dorsal proteins, contains no stretches of glutamines, prolines, or acidic amino acids and therefore may be a novel activation domain. Lesions in the v-rel protein that diminished or abolished oncogenic transformation of avian spleen cells correspondingly affected transcription activation by region I. Region II, located in the carboxy terminus of the c-rel protein, is highly acidic. Region II is not present in the v-rel protein or in a transforming mutant derivative of the c-rel protein. Our results show that the oncogenicity of Rel proteins requires activation region I and suggest that the biological function of rel and dorsal proteins depends on transcription activation by this region.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111443      PMCID: PMC360645          DOI: 10.1128/mcb.10.6.2840-2847.1990

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

1.  Transcriptional activation by the v-myb oncogene and its cellular progenitor, c-myb.

Authors:  K Weston; J M Bishop
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

2.  Structure of a mammalian c-rel protein deduced from the nucleotide sequence of murine cDNA clones.

Authors:  R J Grumont; S Gerondakis
Journal:  Oncogene Res       Date:  1989

3.  Transcription activation by the adenovirus E1a protein.

Authors:  J W Lillie; M R Green
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

4.  Viral rel and cellular rel associate with cellular proteins in transformed and normal cells.

Authors:  L E Morrison; N Kabrun; S Mudri; M J Hayman; P J Enrietto
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

5.  Gene activation and DNA binding by Drosophila Ubx and abd-A proteins.

Authors:  M L Samson; L Jackson-Grusby; R Brent
Journal:  Cell       Date:  1989-06-16       Impact factor: 41.582

6.  DNA specificity of the bicoid activator protein is determined by homeodomain recognition helix residue 9.

Authors:  S D Hanes; R Brent
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

7.  The dorsal protein is distributed in a gradient in early Drosophila embryos.

Authors:  R Steward; S B Zusman; L H Huang; P Schedl
Journal:  Cell       Date:  1988-11-04       Impact factor: 41.582

8.  Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist.

Authors:  K Damm; C C Thompson; R M Evans
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

9.  p59v-rel, the transforming protein of reticuloendotheliosis virus, is complexed with at least four other proteins in transformed chicken lymphoid cells.

Authors:  S Simek; N R Rice
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

10.  The Drosophila fushi tarazu polypeptide is a DNA-binding transcriptional activator in yeast cells.

Authors:  V D Fitzpatrick; C J Ingles
Journal:  Nature       Date:  1989-02-16       Impact factor: 49.962

View more
  57 in total

1.  Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.

Authors:  Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription.

Authors:  G J Kato; J Barrett; M Villa-Garcia; C V Dang
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

3.  The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.

Authors:  W H Walker; B Stein; P A Ganchi; J A Hoffman; P A Kaufman; D W Ballard; M Hannink; W C Greene
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  c-rel activates but v-rel suppresses transcription from kappa B sites.

Authors:  J Inoue; L D Kerr; L J Ransone; E Bengal; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

5.  Fused protein domains inhibit DNA binding by LexA.

Authors:  E A Golemis; R Brent
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

6.  The C terminus of the NF-kappa B p50 precursor and an I kappa B isoform contain transcription activation domains.

Authors:  P J Morin; T D Gilmore
Journal:  Nucleic Acids Res       Date:  1992-05-25       Impact factor: 16.971

7.  RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B.

Authors:  R P Ryseck; P Bull; M Takamiya; V Bours; U Siebenlist; P Dobrzanski; R Bravo
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

8.  Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative.

Authors:  S M Ruben; R Narayanan; J F Klement; C H Chen; C A Rosen
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

9.  Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation.

Authors:  N D Perkins; R M Schmid; C S Duckett; K Leung; N R Rice; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression.

Authors:  D W Ballard; E P Dixon; N J Peffer; H Bogerd; S Doerre; B Stein; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.